Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: TIKOSYN

« Back to Dashboard
Tikosyn is a drug marketed by Pfizer and is included in one NDA. It is available from one supplier. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty patent family members in forty-five countries.

The generic ingredient in TIKOSYN is dofetilide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dofetilide profile page.

Summary for Tradename: TIKOSYN

Suppliers / Packagers: see list9

Pharmacology for Tradename: TIKOSYN

Drug ClassAntiarrhythmic

Clinical Trials for: TIKOSYN

Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block
Status: Completed Condition: Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
Status: Completed Condition: Long QT Syndrome

Genetics of QT Prolongation With Antiarrhythmics
Status: Recruiting Condition: Long QT Syndrome; Drug Toxicity

PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide
Status: Not yet recruiting Condition: Paroxysmal Atrial Fibrillation; Persistent Atrial Fibrillation

Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Status: Completed Condition: Drug-induced Surface ECG Changes

High Intensity Focused Ultrasound (HIFU) Ablation System Study
Status: Suspended Condition: Atrial Fibrillation

Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients
Status: Completed Condition: Cardiac Arrhythmia; Qt Interval, Variation in

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study
Status: Terminated Condition: Atrial Fibrillation; Heart Failure

Catheter Ablation for Recently Diagnosed Paroxysmal Atrial Fibrillation
Status: Withdrawn Condition: Atrial Fibrillation

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation
Status: Completed Condition: Atrial Fibrillation

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CAPSULE;ORAL020931-001Oct 1, 1999RXNo6,124,363<disabled> <disabled>
CAPSULE;ORAL020931-002Oct 1, 1999RXNo6,124,363<disabled> <disabled>
CAPSULE;ORAL020931-003Oct 1, 1999RXYes6,124,363<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: TIKOSYN

Drugname Dosage Strength RLD Submissiondate
dofetilideCapsules0.125 mg, 0.25 mg, and 0.5 mgTikosyn5/1/2014

International Patent Family for Tradename: TIKOSYN

Country Document Number Publication Date
Iceland2179Dec 15, 2006
World Intellectual Property Organization (WIPO)9921829May 06, 1999
China1278246Dec 27, 2000
United Kingdom9722662Dec 24, 1997
Norway20002191Apr 27, 2000
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn